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Abstract  
Objective: Hypoglycemia has been linked to persistent increases in cardiovascular (CV) 
mortality in type 2 diabetes after the event. Our aim was to examine acute and downstream 
effects of hypoglycemia on markers of thrombosis risk and inflammation in type 2 diabetes.  
Research Design and Methods: Twelve type 2 diabetes individuals with no history of CV 
disease and 11 age- and BMI-matched nondiabetic volunteers underwent paired 
hyperinsulinemic euglycemic (glucose 6mmol/l for two 60 minute periods) and 
hypoglycemic clamps (glucose 2.5mmol/l for two 60 minute periods) on separate occasions 
on Day 0. Fibrin clot properties, platelet reactivity and inflammatory markers were measured 
at baseline, end of and following recovery from initial clamp, day 1 and day 7 using validated 
assays and electron microscopy. 
Results: Euglycemic hyperinsulinemia reduced platelet reactivity, decreased fibrin clot 
density and improved fibrinolytic efficiency in both groups. Platelet reactivity and 
aggregation increased during acute hypoglycemia in both groups, resolving at recovery.  In 
type 2 diabetes, clot lysis times and clot maximum absorbance increased up to day 7 
(p=0.002 and p=0.001 versus euglycemia respectively), but clots from nondiabetic controls 
showed limited changes. Fibrin network density increased ǻ fibers/µm2 at day 7 
following the hypoglycemic clamp (p<0.01 for glycemic arm) while fibrinogen and 
complement C3 increased following hypoglycemia up to day 7 in type 2 diabetes only. 
Conclusions: Antecedent hypoglycemia has acute and persistent prothrombotic effects, 
lasting at least 7 days, that were enhanced in individuals with type 2 diabetes.  These findings 
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identify mechanisms by which hypoglycemia might increase short and medium-term risk of 
CV mortality. 
 
Abbreviations 
5HT – 5 hydroxytryptamine 
AUC-  Area under the curve 
ADP adenosine diphosphate 
CoV – coefficient of variation 
CV - cardiovascular 
CRP - C reactive protein 
IL6 - interleukin 6 
MA  - Maximum absorbance 
PAI-1 - Plasminogen activator inhibitor 1 
T1DM – Type 1 diabetes mellitus 
type 2 diabetes – Type 2 diabetes mellitus 
vWF von Willebrand factor 
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Cardiovascular (CV) disease is the leading cause of death in type 2 diabetes mellitus (type 2 
diabetes). A number of large clinical trials have attempted to address the role of intensive 
glucose control on vascular events and have shown either no reduction (1; 2) or an increase 
in mortality (3). Hypoglycemia is associated with increased cardiovascular mortality (2; 4)  
but evidence establishing cause and effect is lacking. In interventional trials, the increased 
mortality associated with hypoglycemia extended well beyond the acute event, with elevated 
risk months later (2). Mechanisms by which hypoglycemia might lead to increased 
cardiovascular mortality in the short-to-medium term are unclear.  
Platelet hyperreactivity, altered fibrin clot characteristics and hypofibrinolysis have 
been linked to excess cardiovascular events, especially in type 2 diabetes (5). Experimental 
hypoglycemia in people with type 1 diabetes can increase platelet aggregation (6) and 
inflammatory markers,  including CD40 expression and soluble CD40 ligand, platelet-
monocyte aggregates, plasma levels of vascular adhesion molecules and P-selectin (7; 8). 
Repeated episodes of hypoglycemia impair nitric oxide-mediated endothelial function and 
increase thrombin/antithrombin complex(9). In clinical studies, hypoglycemia increased factor 
VIII and von Willebrand factor (vWF), which are procoagulant (10).  
However, studies examining the longer-term effects of hypoglycemia on thrombotic and 
inflammatory markers remain scarce. In particular, no study to date has studied prothrombotic 
changes in individuals with type 2 diabetes in response to hypoglycemia, where insulin 
resistance and clustering of metabolic risk factors may differentiate them from those with 
T1DM, predisposing them to a state of depressed fibrinolysis. Antecedent hypoglycemia has 
been shown to alter autonomic responses and decrease vagal activity downstream of the episode 
  
5 
 
 
(11; 12). Suppression of cholinergic anti-inflammatory pathways (13) may lead to 
prothrombotic and proinflammatory responses following hypoglycemia. 
We hypothesised that hypoglycemia might oppose the CV benefits of intensive 
glycemic control by inducing prothrombotic responses both during the episode and 
downstream. Thus the aim of this study was to investigate the effects of hypoglycemia in type 
2 diabetes patients on key thrombotic mechanisms including i) fibrin clot structure and 
fibrinolysis, ii) platelet reactivity and activation, and iii) plasma levels of inflammatory 
markers.  We studied prothrombotic changes during acute hypoglycemia and up to seven 
days after experimentally-induced moderate hypoglycemia in both individuals with type 2 
diabetes and matched healthy controls.  
Research Design and Methods 
Participants 
12 participants with type 2 diabetes, aged between 18 and 65 years and with HbA1c 6.5-
10.5% (48mmol/mol-91mmol/mol), were recruited from Sheffield Teaching Hospitals 
(Sheffield, United Kingdom) outpatient clinics between 2011 and 2014. Eleven age- and 
BMI-matched non-diabetic individuals were recruited as controls from staff at Sheffield 
Teaching Hospitals and The University of Sheffield (Sheffield, United Kingdom).  The same 
participants also had cardiac electrophysiological measurements recorded during the  
morning hypersinsulinemic clamps in a study of the effect of hypoglycemia on autonomic 
function and repolarisation (14).  Participants with diabetes were taking oral hypoglycemic 
agents and/or glucagon-like peptide -1 (GLP-1) analogues and/or insulin for  two years. 
Exclusion criteria included: previous myocardial infarction, ischemic heart disease, cardiac 
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arrhythmias, stroke or peripheral vascular disease, or other known cardiovascular disease; 
epilepsy; untreated hyperthyroidism; pregnancy; serious intercurrent illness.  None were 
taking antiplatelet agents or anticoagulants apart from two patients with diabetes taking 
aspirin. All subjects had normal full blood count, renal function (eGFR >60 mL/min/1.73 
m2), electrocardiogram at baseline, and cardiac autonomic function using standard autonomic 
function tests (15). All participants gave written informed consent. The study was approved 
by the local Research Ethics committee.  
Study design 
Individuals participated in paired hyperinsulinemic euglycemic and hypoglycemic clamp 
studies separated by at least 4 but no more than 8 weeks to minimize carry-over effects.  We 
used a cross-over design such that each participant served as his or her own control to reduce 
variability. Euglycemic studies preceded hypoglycemic studies as hypoglycemia may have 
persistent effects of the cardiovascular system. In previous studies, two periods of 
hypoglycemia resulted in altered autonomic and vagal function that could lead to 
proinflammatory and prothrombotic effects in the days following hypoglycemia (11; 12). In 
one study, these changes were observed up to 6 days later (11). Thus, in the hypoglycemic arm, 
arterialized blood glucose was maintained at 2.5 mmol/l for two 60-minute periods in the 
morning and afternoon with rapid-acting intravenous insulin at 120 and 240 mU/m2/min 
respectively, alongside a variable infusion of 20% dextrose.  Participants were blinded to blood 
glucose levels. Blood glucose was raised to euglycemic levels between morning and afternoon 
hypoglycemic clamps. In the euglycemic arm, arterialized blood glucose was maintained at 6 
mmol/l for 60 minutes during both morning and afternoon, using similar rates of insulin 
infusion used during hypoglycemia. Insulin was administered at the same rates in both subject 
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groups. Prothrombotic and inflammatory markers were measured at the end of the morning 
clamp and at recovery (30 minutes after end of morning clamp) but not during the afternoon 
clamp. To investigate downstream effects, prothrombotic and inflammatory markers were also 
measured in the morning at 1 and 7 days following both euglycemic and hypoglycemic studies. 
The study design is outlined in Fig. 1 and details of the hyperinsulinemic clamp protocol are 
further described in supplementary methods S1.  
Biochemical measurements 
For epinephrine and norepinephrine, whole blood (6 mL) was collected into chilled lithium-
KHSDULQWXEHVFRQWDLQLQJȝ/ EGTA/glutathione as a preservative. These were assayed by 
high-performance liquid chromatography (inter-assay coefficient of variation (CoV) 
norepinephrine 6.03% and epinephrine 15.9%). For free insulin, whole blood (3 mL) was 
collected into a 6-mL lithium-heparin tube and immediately subjected to centrifugation. The 
resulting plasma (0.5 mL) was added to a chilled plastic tube containing 0.5 mL polyethylene 
glycol (PEG) for precipitation of immune complexes and mixed. The product was analysed 
by an immunometric assay (Invitron Insulin ELISA, Invitron Ltd, Monmouth, UK, interassay 
CoV 7.1%). Serum cortisol analysed from 4ml venous blood collected in serum separator 
tube was measured using a commercial immunoassay (Roche e602 serum cortisol assay, 
Roche Diagnostics, West Sussex, UK, interassay CoV 3.2%). Biochemical parameters were 
measured at baseline and at end of euglycemic and hypoglycemic arms in both groups. 
Turbidimetric and lysis assay 
Venous blood was collected into tubes containing 3.2% sodium citrate (BD Vacutainer Glass 
Citrate Tube) on ice. Ex-vivo fibrin polymerisation characteristics of plasma samples were 
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investigated by a validated turbidimetric clotting assay (16), described in detail under 
supplementary methods S2. 
Markers of fibrin dynamics and inflammation 
Fibrinogen and PAI-1 assays were performed on venous blood (4.5 mL) collected into tubes 
containing 3.2% buffered sodium citrate solute (BD Vacutainer Glass Citrate Tube). High-
sensitivity C-reactive protein (hsCRP) was analysed using an immunoturbidmetric assay 
(Cardiac C reactive protein (Latex) high sensitivity, Roche Diagnostics, Indianopolis, USA). 
Interleukin-6 (IL6) was determined using cytometric bead array (Human IL6 Flex set, BD 
Biosciences, Oxford, UK). Complement C3 plasma levels, a protein that is incorporated into 
the fibrin clot and modulates fibrinolysis (17), were determined using ELISA (Biosources, 
San Diego, USA). Further details are described in supplementary methods S2. 
Scanning electron microscopy 
Pooled samples of plasma were analysed from 10 type 2 diabetes and 10 non-DM subjects. 
Fibrin clots were made as previously reported (18) and described in detail in the supplementary 
material (S 2).  
Platelet impedance aggregometry 
Platelet aggregation was analysed using multiple electrode impedance aggregometry 
(Multiplate ®, Roche Diagnostics, Switzerland) and described in detail in supplementary 
methods S2.  
Platelet P-selectin expression 
Hirudin-anticoagulated blood was added to tubes containing PE Cy5 mouse anti-CD62P 
antibody (BD Biosciences, Oxford, UK) and platelet marker CD41a (BD Biosciences, Oxford 
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UK) for measurement of platelet P-selectin expression, with detailed description of the assay 
provided in supplementary methods S2.  
Statistical analysis 
Baseline demographic data and prothrombotic and inflammatory markers are summarised as 
mean (SD) for parametric data, unless otherwise stated, or median (interquartile range) for 
nonparametric data. hsCRP and IL6 were logarithmically transformed due to a skewed 
distribution. End-of-clamp blood glucose and hormone concentrations were compared 
between euglycemic and hypoglycemic timepoints using two-way ANOVA. 
 We used a linear mixed model with repeated measures to compare i) whether there was 
significant change in prothrombotic markers over time within glycemic arms in each subject 
group and ii) effect of glycemic arm on changes in prothrombotic markers in each subject 
group.   For analysis i), timepoint was specified as a fixed effect with multiple comparisons 
against baseline adjusted by the Sidak correction. In mixed-model analysis ii), glycemic arm, 
time and interaction between glycemic arm and time were specified as fixed effects and the 
subject as random effect. Glycemic arm and timepoint were specified as repeated measures 
within each subject. Repeated measures were fitted with an unstructured, compound 
symmetry or autoregressive 1 covariance structure and the model with the best fit (lowest 
Akaike’s information criterion) was selected. p values were obtained by restricted maximum 
likelihood estimation. The effect of glycemic arm and interaction between time and glycemic 
arm on fiber network density and fibrin thickness were analysed using two-way repeated-
measures ANOVA. We further calculated the within-individual correlations between clot MA 
or clot lysis time with fibrinogen, PAI-1 and C3, taking into account repeated measures, 
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based on the ANCOVA method (19). A p value of < 0.05 was considered significant. Results 
were analysed using SPSS (IBM, SPSS Statistics v20).  
 Based on our initial pilot data, a sample size of 10 subjects per group had a power of 
81% to detect a clinically-relevant 15% difference in clot lysis time, assuming a SD of 100s. 
We aimed to recruit 12-13 subjects in each group, allowing for a 20-30% drop out rate. 
Results 
Baseline characteristics 
Twelve patients with type 2 diabetes (9 male) and 11 individuals without diabetes (5 male) 
participated in the study. Participants with diabetes were similar in age, 54 (50-58) years, 
compared with 52(47-59) years in the control group (p = 0.90). The mean BMI was 
comparable: 34±5 kg/m2 in the diabetes group versus 31±8 kg/m2 in the non-DM group 
(p=0.18). The median duration of  diabetes was 10 (8-12) years and mean HbA1c was 
7.8±1.3% (62±14 mmol/mol). Among patients with diabetes, five were taking oral 
hypoglycemic agents only, 5 were taking oral hypoglycemic agents and a GLP-1 analogue, 
and two were on oral hypoglycemic agents and basal insulin.  Baseline prothrombotic and 
inflammatory markers are shown in supplementary table S3.  Subjects with diabetes had 
higher platelet reactivity to ADP but no significant differences were detected in fibrinogen, 
PAI-1, C3 and hsCRP plasma levels (supplementary table S3). 
Blood glucose and counter-regulatory hormones 
Blood glucose levels were similar at end of morning euglycemic and hypoglycemic clamps in 
both groups (supplementary table S4).  Glucose targets were reached during afternoon clamps 
within each arm.  During day 1, blood glucose was higher following hypoglycemic clamps 
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compared with euglycemia in the diabetes group only. Blood glucose levels were similar 
between glycemic arms at day 7. subjects with diabetes did not report symptomatic 
hypoglycemia or capillary glucose values below 3mmol/l in the week following each clamp. 
Median (IQR) free insulin levels at 120 minutes were 576 (468-627) pmol/L during euglycemia 
and 689 (477-1076) pmol/L during hypoglycemia in the diabetes group. In those without 
diabetes, these were 865 (509-952) pmol/L in the euglycemic arm and 665 (468-967) pmol/L 
in the hypoglycemic arm. Insulin levels between groups during both euglycemia and 
hypoglycemia were not different (p = 0.23). 
Counter-regulatory hormones were unchanged during euglycemia (supplementary table S4). 
During acute hypoglycemia, epinephrine, norepinephrine and cortisol increased significantly 
(all p<0.05 versus baseline) similarly in both groups (supplementary table S4). Plasma 
epinephrine and cortisol returned to baseline at day 1 and day 7 following both arms in both 
subject groups. However, in the non-diabetes group, plasma norepinephrine levels increased 
significantly at day 1 after both clamps. 
Fibrin clot properties 
Clot lysis time 
In individuals without diabetes, clot lysis times decreased following euglycemia (from 
729±216 to 611±159s, - ǻ6±110, p=0.001 versus baseline) but returned to baseline at day 1 
(Fig 2a). There were no changes in clot lysis times in the hypoglycemic arm in the non-
diabetes group. In individuals with diabetes, clot lysis times decreased at the end of 
euglycemic clamp ǻ-81±86s) but were prolonged at the end of hypoglycemia, with further 
increases DWGD\ǻ1VDQGGD\ǻ±107s). Changes in clot lysis times were 
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significantly different between euglycemic and hypoglycemic arms in individuals with 
diabetes (p=0.001, Fig 2a). 
Clot maximum absorbance  
In controls, clot MA decreased at the end of both clamps, but to a lesser extent during 
K\SRJO\FHPLDǻ-$8FRPSDUHGZLWKHXJO\FHPLDǻ-0.05±0.05 AU) (p=0.02 for 
glycemic arm) (Fig 2b).   In individuals with diabetes, clot MA decreased during euglycemia 
and during recovery.  There was a non-significant increase in clot MA at the end of 
hypoglycemia (ǻ$8), which resolved at recovery, followed by gradual increases 
at day 1 and 7 (Fig. 2b). There were significant differences in clot MA between glycemic 
arms in the diabetes group (p=0.002) and interaction between time and glycemic arm 
(p=0.02). 
Scanning Electron Microscopy 
Fibrin Diameter 
Fibrin diameter did not change significantly during euglycemia or hypoglycemia in the non-
diabetes group (Fig 3a). In diabetes individuals, there were no changes in fibrin fiber diameter 
during euglycemia, which increased at day 1 and day 7 following hypoglycemia (p<0.01 versus 
euglycemia at equivalent timepoints) (Fig 3a). There was a significant difference between 
glycemic arms (p<0.0001) and in the interaction between time and glycemic arm (p<0.0001). 
Fibrin Network Density 
In the non-diabetes group, fiber network density decreased at day 1 after euglycemia compared 
to no change following hypoglycemia (p <0.001 for glycemic arm). The fibrin network density 
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returned to baseline at day 7 following euglycemia but increased at day 7 following 
hypoglycemia (p<0.01 for glycemic arm) (Fig 3b). 
In the diabetes group, fiber network density decreased at day 7 following euglycemia, whilst 
following hypoglycemia, there was an increase in fiber network density at day 1 and  day 7 
(both p<0.01 for glycemic arm) (Fig 3b). There were significant differences between the 
glycemic arms and the interaction between glycemic arm and time in both the diabetes and 
non-DM groups (both p<0.001). Representative examples of scanning electron micrographs of 
pooled fibrin clots are shown in Fig. 3c. 
Coagulation proteins 
In the non-diabetes group, fibrinogen tended to decrease at the end of the clamp and recover 
similarly during both euglycemia and hypoglycemia. However, in the diabetes group, 
fibrinogen levels did not change during euglycemia but increased ǻmg/mL at day 1 
DQG ǻ0.69mg/mL at day 7 following hypoglycemia (p=0.05 for glycemic arm) 
(supplementary Fig S5a). 
PAI-1 falls in both diabetes and control subjects were similar during euglycemia and 
hypoglycemia (supplementary Fig. S5b). PAI-1 decreased in the controls during euglycemia 
and hypoglycemia (p=0.15 and p=0.005 for time respectively) with no significant differences 
between the arms (p=0.56). In type 2 diabetes subjects, PAI-1 decreased from baseline to ǻ-
811±204pg/mL at the end of euglycemia (p=0.02 versus baseline) and remained lower at day 
7. PAI-1 decreased to a similar extent during hypoglycemia (ǻ-888±256, p=0.02 versus 
baseline) with no differences detected between glycemic arms (p=0.85).  
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Change in clot MA correlated with changes in fibrinogen (r=0.98, p<0.001), PAI-1 (r=0.99, 
p<0.001) and C3 (r = 0.99, p<0.001) across both groups. Change in clot lysis time correlated 
with changes in fibrinogen (r=0.98, p<0.001), PAI-1 (r=0.99, p<0.001) and C3 (r = 0.98, 
p<0.00). There was no correlation between epinephrine, norepinephrine and clot MA or lysis 
times. 
Inflammatory markers 
In the non-diabetes group, C3 levels were similar during euglycemia and hypoglycemia and 
did not change significantly (supplementary Fig S5c). C3 levels did not change during 
euglycemia in the diabetes group but tended to rise at day 7 following hypoglycemia (from 
99±5 at hypoglycemic baseline to 108±4 mg/mL at day 7).  
In non-diabetes individuals, hsCRP increased similarly at day 1 following euglycemia and 
hypoglycemia, in both glycemic arms (supplementary Fig. S5d). In diabetes individuals, 
hsCRP decreased following euglycemia at day 7 (log hsCRP - ǻ, p=0.009 versus 
baseline) compared with no change following hypoglycemia (ORJKV&53ǻDWGD\). 
There was a significant interaction between glycemic arm and time (p= 0.04). 
In the non-diabetes group, IL-6 was higher at day 1 following euglycemia but did not change 
following hypoglycemia (data not shown). In the diabetes group, IL-6 did not change during 
the euglycemic arm, and trended towards an increase in IL-6 following hypoglycemia at day 
7.  
Platelet reactivity and activation 
Collagen- and ADP-induced platelet aggregation 
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In non-diabetes individuals, there was a non-significant change in collagen-induced platelet 
aggregation during euglycemia (Fig 4a). During hypoglycemia, collagen-induced platelet 
aggregation increased significantly higher compared to euglycemia, which resolved at 
recovery. The overall difference in platelet aggregation response to collagen between arms 
was significant (p=0.04). 
 In diabetes individuals, collagen-induced platelet aggregation tended to decrease during 
acute euglycemia ǻ-15±23 U, p=0.11 versus baseline) in contrast to an increase following 
hypoglycemia (p<0.01 between glycemic arms), persisting to the recovery period but not 
beyond. There was a significant interaction between time and glycemic arm (p=0.03). 
ADP-induced platelet aggregation decreased in diabetes subjects during euglycemia 
compared to an increase at the end of hypoglycemia (p=0.03 between arms). In the non-
diabetes group, secondary rises in platelet aggregation induced by both collagen and ADP at 
day 1 occurred following both hypoglycemia and euglycemia (Fig 4a and b). 
There were no significant changes in platelet reactivity to 5HT during euglycemia in both 
groups (Fig 4c). There were trends towards increased platelet reactivity following 
hypoglycemia in both groups, resolving at recovery. In non-diabetes subjects, no significant 
changes in platelet activation occurred during euglycemia. Platelet activation tended to 
increase following hypoglycemia and at day 1 with no overall difference between arms (Fig 
4d). In diabetes individuals, platelet activation, as measured by unstimulated P-selectin 
expression, decreased following euglycemia, maximally at day 1 but increased immediately 
following hypoglycemia (p=0.01 for glycemic arm) (Fig 4d).  
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Conclusions 
To our knowledge, this is the first study investigating the effects of hypoglycemia on both 
cellular and protein arms of the thrombosis pathway in the period beyond a hypoglycemic 
challenge. The novel findings include: i) hypoglycemia was associated with early and late 
prothrombotic changes in the fibrin network in the diabetes group but less evident in healthy 
controls; ii) a rise in fibrinogen and C3 levels that may contribute to late prothrombotic 
changes in fibrin network properties; and iii) hypoglycemia enhanced platelet reactivity in 
individuals with and without diabetes, lasting less than 24 hours following the event.  
The anti-aggregatory, anti-inflammatory and profibrinolytic responses to euglycemic 
hyperinsulinemia are consistent with previous human studies (20; 21). In the present work, a 
striking observation was the difference in clot lysis time between euglycemia and 
hypoglycemia in the diabetes group. Initially, the decrease in clot lysis time during 
euglycemia may be explained by a reduction in PAI-1. Insulin-mediated suppression of 
fibrinogen synthesis may also result in enhanced clot lysis, but is unlikely to contribute to 
early changes given the long half-life of the protein, unlike PAI-1. On the other hand, early 
prolongation in clot lysis in the diabetes group does not appear to be PAI-1-mediated as 
protein levels were reduced following hypoglycemic clamps. In a previous study, PAI-1 was 
decreased during both hyperinsulinemic hypoglycemia and euglycemia in type 1 diabetes 
individuals; however, the authors found increased PAI-1 following hypoglycemia in healthy 
controls (8). 
A novel and intriguing observation is the persistent effect of hypoglycemia on clot density 
and impaired fibrinolysis, at least 7 days following hypoglycemia in the diabetes group but 
not in controls. This finding may be important clinically, particularly in individuals at higher 
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vascular risk. The mechanisms for the late impairment in lysis are not entirely clear, although 
the rise in fibrinogen and complement C3 plasma levels provide plausible explanations. 
Increased levels of fibrinogen are associated with denser clots, as we have previously shown 
(18), which may impair fibrinolysis. This is supported by an observational study in type 2 
diabetes; low fasting glucose was associated with denser ex-vivo fibrin clots as compared 
with fasting glucose in the normal range (22). We have demonstrated that C3 modulates clot 
lysis independently of PAI-1 and this effect is particularly pronounced in individuals with 
diabetes (17; 23). Taken together, it is possible that repeated hypoglycemic episodes lead to a 
state of chronic low-grade inflammation, resulting in elevated fibrinogen and C3 levels, 
which in turn compromises fibrinolysis. However, we cannot exclude the possibility that 
other plasma components may also have an effect. Gogtidize-Joy and colleagues 
demonstrated that nitric oxide-mediated endothelial dysfunction, which creates an 
inflammatory environment, was exaggerated by repeated experimental hypoglycemia 24 
hours later, but effects beyond 48 hours were not reported (9).   
We also showed that hypoglycemia modulates platelet reactivity in type 2 diabetes, 
probably mediated by catecholamine release, but the effects are short-lived. Our results are 
consistent with previous reports of individuals with type 1 diabetes  demonstrating increased 
platelet reactivity during acute hypoglycemia (24). The hypoglycemia-mediated increase in 
platelet reactivity can  be abolished by Į-UHFHSWRUEORFNDGHLPSOLFDWLQJĮ2 adrenoreceptors in 
mediating this effect (6). In contrast to fibrin clot studies, we did not observe consistent 
differences between platelet responses to acute hypoglycemia in the groups studied.  
Our data identify a mechanism whereby hypoglycemia could contribute to increased 
CV mortality by opposing the benefits of intensive glycemic control. In a post-hoc analysis of 
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the NICE-SUGAR study, which reported excess mortality in patients treated to tight glucose 
levels, the median time to death from a hypoglycemic event was 7 days for moderate 
hypoglycemia and 8 days for severe (25). The time course matches our findings of a 
worsening atherothrombotic risk profile 1 week after hypoglycemia. In the ADVANCE and 
VADT trials, the increased CV risk extended for many months after a severe hypoglycemic 
event and it is unlikely that the changes we observed would persist over this period.  On the 
other hand, less severe episodes (equivalent to those induced in this study) were not measured 
consistently in these trials.   They are arguably occurring more frequently in those 
experiencing severe events and if recurrent, might contribute to thrombotic events, 
particularly in those at increased CV risk. 
Our study had the following relevant limitations.  First, the relatively small number of 
participants, while adequate to demonstrate changes in fibrin clot properties, may have left us 
short of statistical power to identify subtle differences between type 2 diabetes and groups 
without diabetes. However, recruiting individuals into experimental studies is challenging 
and this remains one of the largest studies investigating both type 2 diabetes and controls 
with combined platelet and fibrin network analyses. Second, the experimental model requires 
supra-physiological doses of insulin to maintain stable hypoglycemia, higher than that 
observed during routine clinical care.  This might artefactually diminish prothrombotic and 
proinflammatory changes during experimental hypoglycemia.  Third, two subjects were on 
aspirin treatment, which can affect collagen-induced platelet aggregation and clot lysis (26).  
However, these subjects remained on aspirin throughout the study and displayed similar 
patterns of collagen-induced platelet aggregation to other participants (data not shown).  In 
these studies, we induced hypoglycemia on two occasions during day 0 and we cannot be 
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certain that similar persistent prothrombotic changes would have been observed following a 
single or shorter hypoglycemic episodes. Future studies should be designed to address this.  
For obvious ethical reasons, we did not induce hypoglycemia in individuals with known CV 
disease. It is not known whether the deleterious atherothrombotic effects of hypoglycemia 
would be exaggerated in high-CV-risk patients and the protective effects of insulin 
attenuated, compared with our study group.  
 In conclusion, we have shown that two episodes of moderate hypoglycemia have 
acute prothrombotic effects in both non-diabetic and type 2 diabetes subjects. We have also 
demonstrated that the impact of moderate, short-lived hypoglycemia is maintained for at least 
7 days after the event, with adverse effects on fibrin clot properties, fibrinolysis and 
subclinical inflammation.  These effects were more prominent among individuals with type 2 
diabetes compared to a non-DM control group. We have identified potential mechanisms 
whereby hypoglycemia could increase the risk of CV events during and after an episode and 
so oppose the benefits of intensive glycemic control.  The precise clinical relevance of these 
findings remains to be established by further studies.  Nevertheless, we believe that clinicians 
should be consider our results when addressing vascular health in people with type 2 diabetes 
and choose approaches that minimise hypoglycemia when optimising glycemic management. 
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Figures legends 
Fig. 1 Study design 
Each type 2 diabetes or non-DM subject participated in euglycemic and hypoglycemic clamp 
visits separated by 4 to 8 weeks. Euglycemic clamp preceded hypoglycemic clamps. In the 
euglycemic clamp visit, blood glucose was maintained at 6mmol/L for 60 minutes in the 
morning and 60 minutes in the afternoon. In the hypoglycemic clamp visit, blood glucose was 
maintained at 2.5mmol/L for 60 minutes in the morning and 60 minutes in the afternoon. 
Blood samples for platelet function, clotting assays, coagulation proteins and 
counterregulatory hormones were collected at baseline, end of clamp at 60 minutes, recovery 
from morning clamp, and then on the morning of day 1 and day 7 after the euglycemic and 
hypoglycemic clamp visits respectively.  EU euglycemic, HYPO hypoglycemic 
Fig. 2 Effect of euglycemia and hypoglycemia on a) clot lysis time and b) clot density by 
turbidimetric and lysis assay 
type 2 diabetes euglycemia (EU)- open square, type 2 diabetes hypoglycemia (HYPO)- 
closed square, non-DM euglycemia- open circle, non-DM hypoglycemia - closed circle. EU 
arm preceded HYPO arm. † p<0.05  †† p<0.01 euglycemia versus hypoglycemia at 
equivalent time points * p<0.05 versus baseline, ** p<0.01 versus baseline. Differences 
between glycemic arm and the interaction between glycemic arm and time by a mixed model 
with repeated measures are shown. Data mean (SE). Abbreviations: AU arbitrary units, MA 
maximum absorbance.  
 
Fig. 3 Fibrin network properties and scanning electron micrographs of fibrin clots 
following euglycemia versus hypoglycemia in DM and non-DM subjects 
 
a) Fiber network density and b) fibrin fiber thickness following euglycemia (EU) (black) 
versus hypoglycemia (HYPO) grey. Fiber thickness was measured for a total number of 160 
fibers (40 fibers measured from 4 different clot areas at each time point) * p<0.01, ** p<0.01, 
****p<0.0001 between euglycemia versus hypoglycemia.  Data mean are (SE) c) 
Visualisation of ex-vivo fibrin clots from pooled plasma samples in type 2 diabetes (n=10) 
and non-DM (n=10) subjects. There is a decrease in the fiber network following euglycemia 
in both groups as opposed to an increase in the network density following hypoglycemia at 
day 7 
Fig. 4 Effect of euglycemia and hypoglycemia on platelet reactivity and platelet 
activation  
Data represent change in value from baseline. Type 2 diabetes euglycemia (EU)- open square, 
type 2 diabetes hypoglycemia (HYPO)- closed square, Non-DM euglycemia- open circle, non-
DM hypoglycemia closed circle. EU arm preceded HYPO arm. † p<0.05  †† p<0.01 
euglycemia versus hypoglycemia at equivalent timepoint * p<0.05 versus baseline, ** p<0.01 
versus baseline. Differences between glycemic arm and interaction between glycemic arm and 
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time by mixed model with repeated measures are shown. Data mean(SE). Abbreviations: AUC 
area under the curve, MFI median fluorescence intensity 
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